Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Advanced Hepatocellular Carcinoma
NCT00459108Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2007
- Primary completion
- Apr 2011
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Started Apr 2007; status: terminated.
02
Drugs
dasatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00459108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00459108.